Form 4: ARS Pharmaceuticals Chief Medical Officer Sarina Tanimoto Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on September 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on September 17, 2024.
- The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
- The shares were sold in two transactions, each for 50,000 shares, at weighted average prices of $12.9305 and $12.9336.
- Following the reported transactions, Tanimoto directly owns 3,407,847 shares of common stock.
- Tanimoto also has indirect ownership through various trusts, including the Sarina Tanimoto Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and trusts held by her spouse.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting insider trading activity. It doesn't inherently convey positive or negative sentiment, but the market's reaction to the news could vary.
Positives
- The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.
Risks
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.
Industry Context
Insider trading activity is closely monitored in the pharmaceutical industry, as company executives often have access to sensitive information regarding drug development and regulatory approvals. These transactions are legal as long as they are pre-planned and disclosed.
Comparison to Industry Standards
- Comparing Sarina Tanimoto's transactions to other pharmaceutical executives' trading activity is difficult without specific data on similar roles and company sizes.
- However, the use of a 10b5-1 plan is a common practice among corporate insiders to avoid accusations of trading on non-public information.
- For example, executives at companies like Pfizer or Johnson & Johnson also utilize 10b5-1 plans for their stock transactions.
Key Dates
| Date | Description |
|---|---|
| 2020-01-07 | Date of Sarina Tanimoto Charitable Remainder UniTrust and Richard E. Lowenthal Charitable Remainder UniTrust |
| 2023-03-31 | Date of establishment of Rule 10b5-1 trading plan |
| 2024-09-17 | Date of stock sale transactions |
| 2024-09-19 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.